XOMA Royalty Corporation
XOMA Royalty Corporation (XOMA): 13 pipeline candidates · 4 upcoming catalysts · ~33 mo cash runway. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
32.5 months
D/E 1.71 · 46% dilution
Lead: Approved
13 candidates
4 upcoming, next in ~1920d
N/A
A transparent, data-derived signal for XOMA Royalty Corporationacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$741.4M
Cash
$138.7M
Quarterly Burn
$12.8M
Runway
32.5 mo
Revenue
$12.3M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (13 candidates)
| Drug | Phase |
|---|---|
| d-fi | Phase 3 |
| dsuvia | Approved |
| ixinity | Approved |
| ixinity | — |
| miplyffa | Approved |
| miplyffa | — |
| ojemda | Approved |
| ovaprene | — |
| seralutinib | Phase 3 |
| sildenafil | — |
Showing 10 of 13 candidates. Sign up for full pipeline.
Upcoming Catalysts (4)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
82
Total value held
$291.8M
| Holder | Shares | Value |
|---|---|---|
| bvf inc/il | 2,590,303 | $81.3M |
| morgan stanley | 1,702,157 | $53.4M |
| fmr llc | 1,302,974 | $40.9M |
| vanguard capital management llc | 1,099,592 | $34.5M |
| blackrock, inc. | 646,914 | $20.3M |
| geode capital management, llc | 229,766 | $7.2M |
| millennium management llc | 204,920 | $6.4M |
| state street corp | 193,148 | $6.1M |
| dimensional fund advisors lp | 133,360 | $4.2M |
| citadel advisors llc | 110,238 | $3.5M |
Showing top 10 of 82 institutional holders of XOMA Royalty Corporation. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in XOMA Royalty Corporation's pipeline?
XOMA Royalty Corporation (XOMA) has 13 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is XOMA Royalty Corporation's lead drug candidate?
XOMA Royalty Corporation's most advanced tracked candidate is d-fi (Phase 3) for dystrophic epidermolysis bullosa.
What is XOMA Royalty Corporation's next catalyst?
XOMA Royalty Corporation's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: MIPLYFFA" — expected September 20, 2031.
What is XOMA Royalty Corporation's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, XOMA Royalty Corporation has approximately 32.5 months of cash runway.
What is XOMA Royalty Corporation's market capitalization?
XOMA Royalty Corporation's market capitalization is approximately $741.4M.
Get the full picture on XOMA Royalty Corporation
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.